As of 2025-09-18, the EV/EBITDA ratio of Syros Pharmaceuticals Inc (SYRS) is 0.18. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SYRS's latest enterprise value is -17.15 mil USD. SYRS's TTM EBITDA according to its financial statements is -95.71 mil USD. Dividing these 2 quantities gives us the above SYRS EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 8.4x - 13.6x | 11.0x |
| Forward P/E multiples | 12.3x - 19.2x | 15.8x |
| Fair Price | (2,980.64) - (3,300.34) | (3,245.00) |
| Upside | -2543307.4% - -2816085.5% | -2768873.9% |
| Date | EV/EBITDA |
| 2025-09-15 | 0.18 |
| 2025-09-12 | 0.18 |
| 2025-09-11 | 0.18 |
| 2025-09-10 | 0.18 |
| 2025-09-09 | 0.18 |
| 2025-09-08 | 0.18 |
| 2025-09-05 | 0.18 |
| 2025-09-04 | 0.18 |
| 2025-09-03 | 0.18 |
| 2025-09-02 | 0.18 |
| 2025-08-29 | 0.18 |
| 2025-08-28 | 0.18 |
| 2025-08-27 | 0.18 |
| 2025-08-26 | 0.18 |
| 2025-08-25 | 0.18 |
| 2025-08-22 | 0.18 |
| 2025-08-21 | 0.18 |
| 2025-08-20 | 0.18 |
| 2025-08-19 | 0.18 |
| 2025-08-18 | 0.18 |
| 2025-08-15 | 0.18 |
| 2025-08-14 | 0.18 |
| 2025-08-13 | 0.18 |
| 2025-08-12 | 0.18 |
| 2025-08-11 | 0.18 |
| 2025-08-08 | 0.18 |
| 2025-08-07 | 0.18 |
| 2025-08-06 | 0.18 |
| 2025-08-05 | 0.18 |
| 2025-08-04 | 0.18 |
| 2025-08-01 | 0.18 |
| 2025-07-31 | 0.18 |
| 2025-07-30 | 0.18 |
| 2025-07-29 | 0.18 |
| 2025-07-28 | 0.18 |
| 2025-07-25 | 0.18 |
| 2025-07-24 | 0.18 |
| 2025-07-23 | 0.18 |
| 2025-07-22 | 0.18 |
| 2025-07-21 | 0.18 |
| 2025-07-18 | 0.18 |
| 2025-07-17 | 0.18 |
| 2025-07-16 | 0.18 |
| 2025-07-15 | 0.18 |
| 2025-07-14 | 0.18 |
| 2025-07-11 | 0.18 |
| 2025-07-10 | 0.18 |
| 2025-07-09 | 0.18 |
| 2025-07-08 | 0.18 |
| 2025-07-07 | 0.18 |